Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the first results of the primary analysis of…
In this video, recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, in Denver, CO, Jeanne McCarthy-Kaiser, PharmD, BCOP,…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Jeanne McCarthy-Kaiser, PharmD, BCOP, of the…
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration…
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic…
Yung Lyou, MD, UC Irvine Health, talks about Selecting Patients for Adjuvant Pancreatic Treatment | Determine Who Has Better Performance…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the Major Impact from HIPEC is Insurance Reimbursement | Insurance Companies Feel…
Edward L. Nelson, MD, UC Irvine Health explains Number of Molecular Targets Are Overwhelming Practitioners | Practitioners Must Know What…
John P. Fruehauf, MD, UC Irvine Health, explains New Agents for BRAF-MEK Inhibition | Binimetinib/Encorafenib at MOASC 2018
Nataliya Mar, MD, UC Irvine Health, Addressing Non-Clear Cell Histology | Did Not Come Across Any Trials at MOASC 2018
Rita Sanghvi Mehta, MD, UC Irvine Health, explains High-Dose Fulvestrant Vs. Loading Dose | Loading Dose Prevents Early Progressions at…
Yung Lyou, MD, UC Irvine Health, talks PRODIGE 24 Showed FOLFIRINOX has Benefits | FOLFIRINOX was Compared to Single-Agent Gemcitabine…
Edward L. Nelson, MD, UC Irvine Health explains Whether to ReBiopsy a Tumor | Give Practitioners Understanding of Modalities at…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the Negative Results from HIPEC Study | Surgery May Still Have Role…
John P. Fruehauf, MD, UC Irvine Health, explains KEYTRUDA & Role in Stage 4 Melanoma | Immunotherapy has Long-Term Benefits…
Nataliya Mar, MD, UC Irvine Health, shares her Urothelial Carcinoma Abstracts | Enfortumab, Erdafitinib were Effective Based on Data at…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach,…
In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, reflects on the differences between the treatment…
Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, speaks about the advances made in leukemia diagnostics and…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach,…
With the recent maturation of novel therapies for acute myeloid leukemia (AML), the field of AML therapeutics is rapidly progressing.…
In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, speaks about the difficulties in diagnosing and…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from…
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses new strategies for clinical trial design in multiple…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses considerations in the treatment of high risk multiple myeloma…
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses two Phase III multiple myeloma (MM) transplantation studies…
Monika Engelhardt, MD, of the University Medical Center Freiburg, Freiburg, Germany, speaking from the 1st European Myeloma Network (EMN) Meeting…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses advances in the classification of high risk multiple myeloma…
Yung Lyou, MD, UC Irvine Health, talks about 3 Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24…
Rita Sanghvi Mehta, MD, UC Irvine Health, explains how Patients were Given Anastrozole + Fulvestrant | Some Patients Over-Represented in…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the HIPEC Study Requires Further Evaluation | Closed United States Intergroup Study…
Edward L. Nelson, MD, UC Irvine Health explains Topics Covered in ASCO 2018 | Precision Medicine, Next-Gen Sequencing, Tumor Cells,…
Exciting updates on obinutuzumab were presented at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm,…
Dr Olivier Casasnovas, from the Department of Hematology, Dijon, France, gives an update on data from the Phase III AHL2011…
Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenströms macroglobulinemia (WM) were presented at…
Great strides have been made in the management of sickle cell disease. Here, Maria Cappellini, of the University of Milan-Foundation…
“Dr Laurie Sehn, of the BC Cancer Agency, Vancouver, BC, Canada presents: ‘Answering the unmet need in one of the…
John Gribben, of Barts Cancer Institute, London, UK, discusses making CAR T-cells happen in Europe. This video was recorded at…
Dr Jing Pan, of Beijing Boren Hospital, Beijing, P.R. China, discusses a new anti-CD22 CAR T-cell immunotherapy for pediatric relapsed/refractory…
HARMONY is Europe’s largest public-private partnership for big data in hematology. Here, Jesús MarÃa Hernández Rivas, HARMONY Alliance Project Coordinator,…
Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Jesús…
Dr Franck Morschhauser, of Centre Hospitalier Universitaire Régional de Lille, Unité GRITA, Lille, France, discusses the question: is RELEVANCE relevant?…
Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Francesca…
Dr Fang Liu, of Chengdu Military General Hospital, Chengdu, Sichuan, P.R. China, discusses first-in-human CLL1-CD33 compound CAR T-cells as a…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the…
Speaking from the American Society of Oncology (ASCO) 2018, held in Chicago, IL, Michael Mauro, MD, of Memorial Sloan Kettering…
In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (MRD) should be…
Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses extending the use of hypomethylating agents from patients…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the…
The recent FDA approval of bosutinib makes it the fourth inhibitor for the frontline treatment of chronic myeloid leukemia (CML),…
One of the major downsides to immunotherapy is its high cost. In this interview, Rafael Fonseca, MD, of the Mayo…
Tyrosine kinase inhibitors (TKIs) are some of the most successful drugs available for the treatment of a myriad hematological cancers.…
The treatment of multiple myeloma (MM) can be very costly. Speaking from the American Society of Oncology (ASCO) 2018 Annual…
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).…
Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the situations in which measurable residual disease (MRD) should and…
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic…
John P. Fruehauf, MD, UC Irvine Health, Axillary Dissection in Stage 2 or 3 Melanoma | No Benefit from Taking…
Nataliya Mar, MD, UC Irvine Health, shares her Abstracts were Metastatic Genitourinary Malignancies | Mix of Urothelial Carcinoma, Prostate Cancer,…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about SWOG S0226 – for Metastatic Breast Cancer | Addition of Fulvestrant…
Nicola Giuliani, MD, PhD, from the University of Parma, Parma, Italy, talks about the clinical approach required when identifying and…
Speaking at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Nicola Giuliani, MD, PhD, from the University…
The future of biology is becoming increasingly technologically-based. In this video, Dominique Bonnet, PhD, of the Francis Crick Institute, London,…
In this video, Dominique Bonnet, PhD, of the Francis Crick Institute, London, UK, outlines her group’s research into the biology…
All types of healthcare, including measurable residual disease (MRD) testing should be available to everyone throughout Europe. Speaking from the…
Measurable residual disease (MRD) testing is revolutionizing our ability to determine the disease state of a patient. In this video,…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, Elizabeth Macintyre, MD, PhD, of the…
Felice Bombaci, from the AIL patient group for chronic myeloid leukemia (CML), Rome, Italy, discusses some important key topics in…
Immunotherapy has been making rapid advancements as of late, especially the area of CAR T-cell therapy. Howard Burris, MD, FACP,…
Patients with metastatic Merkel cell carcinoma (MCC) that does not respond to chemotherapy have a very poor survival rate after…
In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks about prostvac, a novel…
Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Schmid, MD, PhD, FRCP,…
In this interview, Paul Nghiem, MD, PhD, from the University of Washington, Seattle, WA, discusses the results of the Phase…
In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks to us about the…
Cell-free (cf)DNA analysis is frequently used in lung cancer to identify therapeutic targets, but there has also been recent interest…
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS,…
Paul Richardson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the exciting results of the Phase III OPTIMISMM trial (NCT01734928)…
Patients with T-cell leukemias typically have a worse prognosis than those with B-cell malignancies. In this interview, Kimberly Dunsmore, MD,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS,…
The CRB-401 trial (NCT02658929) aims to investigate the efficacy of bb2121 for multiple myeloma (MM) patients. In this interview, recorded…
In this interview, Raúl Córdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, discusses the problems…
Julia Snider, PhD, from Precision Health Economics, San Francisco, CA, talks to us about the social value of the CAR…
Precision, or personalized, medicine has often been regarded as the future of cancer treatment. In this interview, Howard Burris, MD,…
BTK inhibitors like ibrutinib have shown impressive efficacy in treating mantle cell lymphoma (MCL) in the first relapse setting; however,…
Many clinical trials are skewed towards a certain patient population, resulting in biased data. Here, Ruben Mesa, MD, of UT…
Measurable residual disease (MRD) analysis is becoming increasingly commonplace as a prognostic indicator and tool for guiding the management of…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, in Stockholm, Sweden, Thomas Alexander, MD, PhD, of…
BTK inhibition is a popular avenue of treatment research in Waldenström’s macroglobulinemia (WM). In this video, recorded at the 23rd…
Symptom burden in patients with myeloproliferative neoplasms (MPNs), in the form of fatigue, night sweats and weight loss, can remain…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, presented results from the CRB-401 trial (NCT02658929) at the 23rd…
There is an unmet need for treatment options for acute lymphoblastic leukemia (ALL) patients who have relapsed on multiple prior…
The treatment landscape for myeloproliferative neoplasms (MPNs) is constantly evolving, as Ruben Mesa, MD, of UT Health San Antonio Cancer…
Lenalidomide is widely used for multiple myeloma (MM); however, while it is effective, most patients relapse and become lenalidomide-refractory. In…
Understanding the mutations and whole-genome interactions taking place in multiple myeloma (MM) is crucial for disease understanding and therapy research.…
Felice Bombaci, from the AIL patient group for chronic myeloid leukemia (CML), Rome, Italy, discusses some important key topics in…
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic…
Haematopoietic stem cells give rise to the multitude of blood cells in our circulatory system. In this video, Dominique Bonnet,…
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in…
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting…
The MURANO study (NCT02005471) is a Phase III trial looking at rituximab in combination with either bendamustine or venetoclax for…
Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, presents the results of some preclinical and clinical trials investigating the…
Richard Clark, MA, MD, MRCP, FRCPath, of the Royal Liverpool University Hospital, Liverpool, UK, presented the final results of the…
Chemotherapy is becoming increasingly less desirable as a form of treatment, due to its systemic and burdensome nature. Instead, immunotherapy…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of…
Patients with relapsed, transplant ineligible diffuse large B-cell lymphoma (DLBCL) face extremely poor outcomes. In this video, recorded at the…
While the outcome for patients with chronic lymphocytic leukemia (CLL) has significantly improved over the last 30 years due to…
The BCL2 inhibitor venetoclax is just one example of a new therapeutic agent that has allowed patients with chronic lymphocytic…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Simon Rule, MD, of…
Clinical trials are designed to test the effect of new drugs and treatments in a highly controlled environment. While this…
The response of patients with multiple myeloma (MM) to therapy is always variable. Speaking from the 23rd Congress of the…
Mantle cell lymphoma (MCL) outcomes have improved in recent years as a result of an influx of improved treatments, including…
Achievement of a complete response and measurable residual disease (MRD) negativity are associated with improved survival in chronic lymphocytic leukemia…
In this video, Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, presents the first interim analysis of the…
Therapies for acute lymphoblastic leukemia (ALL) have constantly been improving. Indeed, 35 years ago the survival rate for children was…
Defibrotide has previously been studied in post-stem cell transplant patients with veno-occlusive disease with a suitable investigational new drug (IND).…
Follicular lymphoma treatments are improving; however, there are subgroups of patients who still have poor outcomes. Here, Marek Trneny, MD,…
With the many new second generation therapies for chronic myeloid leukemia (CML), there is some debate as to which therapy…
Many tumor cells are able to evade apoptosis, with the potential to survive in the body indefinitely. Here, Shaji Kumar,…
The HORIZON study (NCT02963493) aims to determine the efficacy of melflufen in combination with dexamethasone in relapsed/refractory multiple myeloma (MM).…
Measurable residual disease (MRD) negativity is an important treatment endpoint for many hematological malignancies and has the potential to be…
In this weeks video, Dr. Brian G.M. Durie explains how the ARROW study demonstrated efficacy and low toxicity for weekly…
In this video, Dr. Brian G.M. Durie explains how high-dose melphalan therapy that precedes an ASCT may cause some side…
In this video, Dr. Brian G.M. Durie explains which lifestyle choices can improve myeloma patients outcomes. BOTTOM LINE: Live as…
In this video, Dr. Brian G.M. Durie explains why MRD-negative status and MRD-positive status are not clear indicators for next…
In this weeks video, Dr. Brian G.M. Durie recommends ways myeloma patients can avoid infections, such as using preventative antibiotics,…
In this weeks video, Dr. Brian G.M. Durie discusses the ways patients can learn from one another at IMF-affiliated support…
Locally advanced head and neck cancer is treated with chemotherapy and radiation as standard, with an aim to cure the…
The assessment and diagnostic workup of newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) is evolving, as discussed…
A variety of highlighly anticipated urological oncology research with great potential was shown at the American Society of Oncology (ASCO)…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Grant McArthur, MBBS, BMedSc, PhD,…
The field of genomics is one of great promise, and there is hope that it can be implemented into all…
The aims of treatment for chronic myeloid leukemia (CML) have changed in recent years, as explained here by Susanne Saussele,…
At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Wendy Osborne, MBBS (Hons), MRCP,…
Highlights of promising clinical trials of novel agents for chronic myeloid leukemia (CML) are overviewed here by Susanne Saussele, MD,…
Great strides have been made in the treatment of advanced melanoma; these developments are now being translated into the adjuvant…
Melanoma that has metastasized to the brain is extremely high risk, and such metastasis is more likely in patients with…
Enriqueta Felip, MD, PhD, of Vall dHebron University Hospital, Barcelona, Spain, discusses the VISION trial (NCT02864992) of tepotinib for non-small…
Cetuximab monotherapy is the standard of care for platinum-resistant non-HPV related metastatic head and neck cancer; however, response and survival…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Paolo Ascierto, MD, of the…
Promising genitourinary cancer updates were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.…
While treatments for melanoma have been steadily improving over recent years, patients with brain metastases have consistently had poor outcomes.…
Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting urothelial carcinoma therapy updates from the American Society…
A variety of new therapeutics for melanoma are on the horizon, including IDO, immune checkpoint, LAG-3 and HDAC inhibitors. Here,…
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discusses the promising efficacy data of sacituzumab govitecan, an anti-Trop-2/SN-38…
The treatment of melanoma is undergoing exciting advancements, as discussed here by Paolo Ascierto, MD, of the National Cancer Institute…
At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary, Mark Levis, MD,…
Drug development for multiple myeloma (MM) has recently reached such heights that there is now a plethora of novel inhibitors…
Checkpoint inhibitors are an exciting therapy across a range of cancer types. Speaking from the American Society of Oncology (ASCO)…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Ezra Cohen, MD, FRCPC, FASCO, of…
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, hosted an array of exciting clinical trials…
There have previously been no randomized trials assessing systemic therapy activity for progressive desmoid tumors. Here, Maud Toulmonde, MD, of…
Metastatic head and neck cancer that has progressed following platinum therapy generally has a very poor prognosis. In this video,…
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced…
Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.
In this weeks video, Dr. Brian G.M. Durie provides helpful hints for myeloma patients to follow healthful diets. The BOTTOM…
In this weeks video, Dr. Brian G.M. Durie explains why a Freelite test may be inaccurate. BOTTOM LINE: Discuss abnormal…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for…
Cancer vaccines are a promising immunotherapeutic area, particularly in the field of prostate cancer. Here, Neal Shore, MD, of Carolina…
Steroids were previously administered as a form of treatment for many different conditions, including cancer. However, the previous usage of…
The use of sequential single-gene testing to detect genomic alterations in metastatic non-small cell lung cancer (NSCLC) can be costly,…
The KEYNOTE-189 ( NCT02578680) trial investigated the effects of adding pembrolizumab to cisplatin and pemetrexed in patients with non-small cell…
Prostate cancer therapy has seen radical changes and improvements recently, with a multitude of clinical trials currently underway. Speaking from…
The ATLANTIC trial (NCT02087423) is currently underway to determine the effects of durvalumab on patients with advanced non-small cell lung…
The treatment landscape of metastatic breast cancer (mBC) is advancing rapidly. Here, Aditya Bardia, MD, MPH, of Massachusetts General Hospital,…
In relapsed/refractory diffuse large B-cell lymphoma (DLBCL), response rates are poor for salvage treatments and autologous stem cell transplants. Here,…
New drugs for acute myeloid leukemia (AML) are constantly being developed. In this video, recorded at the 23rd Congress of…
There has been growing evidence that the combination of hypomethylating agents like azacitidine with immune checkpoint inhibitors could be a…
In this video, Lydia Scarfò, MD, of Vita-Salute San Raffaele University, Milan, Italy, describes the studies on chronic lymphocytic leukemia…
A large proportion of acute myeloid leukemia (AML) patients are treated by non-specialist community oncologists, who may not have the…
Epigenetic therapies are constantly developing in the field of acute myeloid leukemia (AML). In this video, recorded at the 23rd…
Acute myeloid leukemia (AML) has shown good responses to immunotherapies, including monoclonal antibodies, immune checkpoint inhibitors and bispecific antibodies. Here,…
Here, Lydia Scarfò, MD, of Vita-Salute San Raffaele University, Milan, Italy, gives an interesting insight about the possible reasons behind…
Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the…
Chemotherapy is ineffective against a certain subset of diffuse large B-cell lymphoma (DLBCL) types. In this video, recorded at the…
Andrew Wei, MBBS, PhD, of Monash University, Melbourne, Australia, presented results from the CAVEAT trial (ACTRN12616000445471) at the 23rd Congress…
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.
Clinical trials have demonstrated the positive response rates for FLT3 inhibitors like quizartinib in relapsed FLT3-mutated acute myeloid leukemia (AML).…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses smoking, asbestos, radon and other risk factors for lung cancer.
Measurable residual disease (MRD) is an important indicator of disease progression and prognosis. Here, Stephan Grupp, MD, PhD, of the…
The use of checkpoint inhibitors in multiple myeloma (MM) is an exciting area. The data from two KEYNOTE studies examining…
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, gives an overview of his top 5 abstract presentations at the…
While CAR T-cells are a potentially revolutionary therapy option across a variety of cancer types, their associated side effects include…
CAR T-cells represent an important step forward in the treatment of a variety of hematological malignancies. At the American Society…
Multiple myeloma (MM) updates in the relapsed/refractory setting at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago,…
Cutting-edge trial data in the field of lymphoma was presented at the American Society of Oncology (ASCO) 2018 Annual Meeting…
In this video, Ryan Cassaday, MD, of the University of Washington, Seattle, WA, gives an overview of recent developments in…
CAR T-cells are an exciting therapeutic avenue for multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital Cancer…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Nathan Fowler, MD, of the MD…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, of…
A number of novel treatment strategies for multiple myeloma (MM) are being studied. A few such studies are discussed here…
Multiple myeloma (MM) is an expensive cancer to treat, with costly drugs that are often used in combination. In this…
Tisagenlecleucel (CTL019), a CAR T-cell agent, was approved for acute lymphoblastic leukemia (ALL) treatment in children and young adults last…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ryan Cassaday, MD, of the…
The anti-BCMA CAR T-cell therapy bb2121 looks extremely promising in multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General…
Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society…
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy…
Benjamin Philip Levy, MD, talks about the data from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in…
Primo N. Lara, Jr., MD, explains whether the TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable…
Howard A. “Skip” Burris III, MD, FACP, FASCO, explains some of the new and exciting concepts in clinical trial design
Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study…
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of…
Julie Gralow, MD, talks about how to differentiate CDK4/6 inhibitors and whether they can be used interchangeably.
Primo N. Lara, Jr., MD, explains the convenience factor of oral TKIs influences decisions related to advanced renal cell carcinoma…
Eunice Wang, MD, talks about The most exciting data coming out of the 2018 Annual Meeting
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how Watson is…
Benjamin Philip Levy, MD, explains whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and…
Richard Goldberg, MD, on preoperative chemotherapy in pancreatic cancer and whether the PREOPANC-1 has influenced the path of treatment
Howard A. “Skip” Burris III, MD, FACP, FASCO, talks about his goals for the 2019 Annual Meeting.
Neelima Denduluri, MD, discusses the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in…
Eunice Wang, MD, talks about the role for nivolumab maintenance in high-risk acute myeloid leukemia (AML) patients
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how data from…
Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in…
Prognoses for patients with relapsed metastatic head and neck cancer that has progressed on prior platinum therapy are poor. Here,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Karim Fizazi, MD, PhD, of the…
Speaking about symptoms can often be a difficult experience for patients, as it can confirm their fears of the disease.…
Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, presented…
In this interview, Karim Fizazi, MD, PhD, of the University of Paris-Sud, Orsay, France gives an overview of the LATITUDE…
The diagnosis of ovarian cancer often occurs in the late stages due to a lack of adequate screening facilities. However,…
Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, David Carbone, MD, PhD, of Ohio…
Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is…
Exciting new data for metastatic renal cell carcinoma (mRCC) was presented at the American Society of Oncology (ASCO) 2018 Annual…
Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting,…
Treatment options for small cell lung cancer (SCLC) have not advanced significantly in the past few decades, and patients with…
Currently, CAR T-cell products are primarily tested in the relapsed setting. However, bringing these novel agents to patients earlier in…
IV administration of daratumumab has several issues, including a long infusion time (~7 h) and the likelihood of infusion-related toxicities.…
CAR T-cell monotherapies have produced promising results; however, the duration of remission needs to be optimized. Here, Jeremy Abramson, MD,…
CAR T-cells represent an exciting new treatment frontier across a variety of blood cancers. We interviewed David Maloney, MD, PhD,…
Ajai Chari, MD, PhD, of Mount Sinai School of Medicine, New York, NY, presented data from the recent Phase Ib…
CAR T-cell monotherapies have produced promising results; however, the duration of remission needs to be optimized. Here, Jeremy Abramson, MD,…
Francesca Gay, MD, of the University of Torino, Torino, Italy, provides an efficacy data update from the FORTE trial (NCT02203643),…
With the recent influx of targeted, highly effective novel agents to the field of acute lymphoblastic leukemia (ALL), there is…
While there are many clinical trials exploring the effect of various novel agents in combination with lenalidomide-dexamethasone therapy in multiple…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the Agreement of a Single IRB Review | Single IRG Approval…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, shares how the Study Brought Together Six Academic Centers | BMS, Apexigen,…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains how No One Else is Focusing on Pancreatic Cancer | Answer…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Focuses on Frontline Metastatic Pancreatic Cancer | Patients…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Follows Patients for a Period of Time in…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about Lead Investigator of Study, Dr. Vonderheide | Develop New Agents…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the combination of Gemcitabine + Abraxane – Standard for Pancreatic Cancer…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about the Trial Combining Immunotherapy & Chemotherapy | Survival will be…
Prof Wee Joo Chng, MD discusses the importance of Minimal Residual Disease (MRD) testing in Multiple Myeloma
Kinase inhibitors are one of the most successful forms of therapy for hematological malignancies, with further potential due to new…
The contemporary viewpoint is that multiple myeloma (MM) is a group of separate diseases, rather than just one type of…
Monika Engelhardt, MD, of the University Medical Center Freiburg, Freiburg, Germany, discusses a promising study conducted at her center using…
In this video, Fabio Malavasi, MD, of the University of Turin, Turin, Italy, discusses immunotherapy in multiple myeloma (MM) from…